RNS Number : 0546X
OptiBiotix Health PLC
17 December 2019

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Anthem BioPharma launches two products formulated with SlimBiome® to the Indian market

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces the commercial launch of two products formulated with SlimBiome® to the Indian market in partnership with Anthem BioPharma and Zeon Life Sciences.

Anthem BioPharma (www.anthembiopharma.com), an Anthem Biosciences Pvt Ltd company, is a fully integrated Indian Pharmaceutical and Biotechnology company with a turnover of £90 million in FY 2019-20 and launched two products formulated with SlimBiome® to the Indian market on 16 December 2019. The products are 1) Metalite - a supplement to aid with effective weight management and 2) Metalite Pro - a high protein meal replacement (www.metalitepro.com).

Pratik Girish Ligade, Marketing & Sales Business Head - Diabetology, commented: *"India is currently one of the most attractive potential markets for the health and wellness industry due to its large, fast urbanizing population. Increasing stress and unhealthy lifestyle, has made nearly 1 out of 4 adults overweight. The main reasons behind this alarming situation is an increase in the consumption of processed food, lower levels of physical activity and increased professional and personal life pressures. Truncal obesity in adults and teens, unhealthy food choices and contamination of food, water and air in cities is creating a perfect storm of lifestyle diseases. Consumers are becoming aware of the serious health risks resulting from their new lifestyle choices and are willing to do something about it. As a result, there is an increase in wellness products and dietary supplements product offerings targeting weight loss, however, there is hardly any clinically tested meal replacement product available in India. It gives Anthem a great opportunity to make an impact in this space, and we believe SlimBiome® will play an important role in addressing the obesity pandemic that continues to increase. We chose SlimBiome® because it is scientifically formulated and clinically proven to function in weight management applications."*

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: *"We are very pleased to announce this commercial launch in partnership with Anthem BioPharma and Zeon Life Sciences, the exclusive manufacturer of SlimBiome® in India. This launch is the start of recurrent revenues in India and we are*

confident in our capacity to replicate similar deals in other markets in the near future now that we have production partners in North America, the UK, Europe and India."

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive *Contact via Walbrook below*

finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel

Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy optibiotix@walbrookpr.com

About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRALLFLDFDLRLIA